Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Argenx ...

Gilead Sciences Inc. closed 15.47% short of its 52-week high of $119.96, which the company reached on March 10th.

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

It's been nearly two-and-a-half years since The Handmaid's Tale's season 5 finale sent June (Elisabeth Moss), Serena (Yvonne ...

The Handmaid’s Tale star revealed six years later that she was pregnant with her first baby. After quietly giving birth, Moss brought her little one to the Hulu set. (The actress has not publicly ...

The Handmaid's Tale' season 6 is here and the final season has a lot of story to wrap up. Here's a refresher on the key phrases and sayings in the Hulu series.

Ever since author Margaret Atwood created the dystopian world in her 1986 novel, The Handmaid's Tale, folks have become ...

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Analysts' ratings for Gilead Sciences (NASDAQ:GILD) over the last quarter vary from bullish to bearish, as provided by 15 analysts. The following table encapsulates their recent ratings ...